Drug Approval | November 24, 2023
Lupin receives tentative approval from USFDA for Canagliflozin Tablets
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
Bromfenac Ophthalmic Solution, 0.07% is indicated for the treatment of postoperative inflammation and reduction of ocular pain
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Lupin Vilfuro-G is the only FDC that uniquely combines Vilanterol, Fluticasone Furoate and Glycopyrronium Bromide
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
The Product will be manufactured at the company's facility in Bengaluru
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Subscribe To Our Newsletter & Stay Updated
